ACRX - AcelRx Pharmaceuticals Inc Stock Price, Fair Value and News

0.89USD0.00 (0.00%)Market Closed

Market Summary

USD0.890.00

Market Closed

0.00%

ACRX Stock Price

View Fullscreen

ACRX RSI Chart

ACRX Valuation

Market Cap

14.6M

Price/Earnings (Trailing)

-1.03

Price/Sales (Trailing)

0.19

EV/EBITDA

-0.34

Price/Free Cashflow

-0.97

ACRX Price/Sales (Trailing)

ACRX Profitability

EBT Margin

-11.49%

Return on Equity

-86.93%

Return on Assets

-49.35%

Free Cashflow Yield

-103.5%

ACRX Fundamentals

ACRX Revenue

Revenue (TTM)

89.6M

ACRX Earnings

Earnings (TTM)

-14.2M

Earnings Growth (Yr)

51.5%

Earnings Growth (Qtr)

12.46%

Breaking Down ACRX Revenue

Last 7 days

-1.1%

Last 30 days

-2.3%

Last 90 days

-18.1%

Trailing 12 Months

-13.1%

How does ACRX drawdown profile look like?

ACRX Financial Health

Current Ratio

5.97

ACRX Investor Care

Shares Dilution (1Y)

55.55%

Diluted EPS (TTM)

-1.65

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	89.6M	0	0	0
2022	23.1M	43.4M	63.7M	84.1M
2021	5.5M	3.1M	3.6M	2.8M
2020	2.2M	4.2M	5.0M	5.4M
2019	2.4M	2.6M	2.8M	2.5M
2018	5.2M	3.4M	2.3M	2.2M
2017	17.4M	15.6M	13.7M	8.0M
2016	22.1M	24.7M	12.7M	17.4M
2015	8.7M	12.2M	15.8M	19.3M
2014	23.4M	17.4M	11.3M	5.2M
2013	3.0M	3.2M	3.6M	29.5M
2012	1.4M	1.7M	2.1M	2.4M
2011	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About AcelRx Pharmaceuticals Inc

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.

CEO	Mr. Vincent J. Angotti
WEBSITE	acelrx.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	19

AcelRx Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for AcelRx Pharmaceuticals Inc? What does ACRX stand for in stocks?

ACRX is the stock ticker symbol of AcelRx Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AcelRx Pharmaceuticals Inc (ACRX)?

As of Thu Jul 25 2024, market cap of AcelRx Pharmaceuticals Inc is 14.61 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ACRX stock?

You can check ACRX's fair value in chart for subscribers.

Is AcelRx Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ACRX is over valued or under valued. Whether AcelRx Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact AcelRx Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ACRX.

What is AcelRx Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, ACRX's PE ratio (Price to Earnings) is -1.03 and Price to Sales (PS) ratio is 0.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ACRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on AcelRx Pharmaceuticals Inc's stock?

In the past 10 years, AcelRx Pharmaceuticals Inc has provided -0.182 (multiply by 100 for percentage) rate of return.